These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 11698228)

  • 41. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
    Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
    Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antivirals update.
    Proj Inf Perspect; 1998 Sep; (25):4-7. PubMed ID: 11365849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.
    Floris-Moore M; Howard AA; Lo Y; Arnsten JH; Santoro N; Schoenbaum EE
    HIV Med; 2006 Oct; 7(7):421-30. PubMed ID: 16925727
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
    Bommenel T; Launay O; Meynard JL; Gilquin J; Katlama C; Lascaux AS; Mahamat A; Martinez V; Pradier C; Rouveix E; Simon A; Costagliola D; Abgrall S;
    J Antimicrob Chemother; 2011 Aug; 66(8):1869-77. PubMed ID: 21636583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients.
    Bucher HC; Kofler A; Nüesch R; Young J; Battegay M; Opravil M
    AIDS; 2003 Nov; 17(17):2451-9. PubMed ID: 14600516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
    Portsmouth S; Stebbing J; Gill J; Mandalia S; Bower M; Nelson M; Bower M; Gazzard B
    AIDS; 2003 Jul; 17(11):F17-22. PubMed ID: 12853764
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Thomas-Geevarghese A; Raghavan S; Minolfo R; Holleran S; Ramakrishnan R; Ormsby B; Karmally W; Ginsberg HN; El-Sadr WM; Albu J; Berglund L
    Am J Clin Nutr; 2005 Jul; 82(1):146-54. PubMed ID: 16002813
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation and management of dyslipidemia in patients with HIV infection.
    Green ML
    J Gen Intern Med; 2002 Oct; 17(10):797-810. PubMed ID: 12390557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.
    Walli R; Herfort O; Michl GM; Demant T; Jäger H; Dieterle C; Bogner JR; Landgraf R; Goebel FD
    AIDS; 1998 Oct; 12(15):F167-73. PubMed ID: 9814858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. AIDS update 1999: viral reservoirs and immune-based therapies.
    Isada CM; Calabrese LH
    Cleve Clin J Med; 1999 May; 66(5):267-9. PubMed ID: 10330777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure.
    Hurwitz BE; Klimas NG; Llabre MM; Maher KJ; Skyler JS; Bilsker MS; McPherson-Baker S; Lawrence PJ; Laperriere AR; Greeson JM; Klaus JR; Lawrence R; Schneiderman N
    Cardiovasc Toxicol; 2004; 4(3):303-16. PubMed ID: 15470277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy.
    Ellis RJ; Marquie-Beck J; Delaney P; Alexander T; Clifford DB; McArthur JC; Simpson DM; Ake C; Collier AC; Gelman BB; McCutchan JA; Morgello S; Grant I;
    Ann Neurol; 2008 Nov; 64(5):566-72. PubMed ID: 19067367
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rapid progression of carotid lesions in HAART-treated HIV-1 patients.
    Maggi P; Perilli F; Lillo A; Gargiulo M; Ferraro S; Grisorio B; Ferrara S; Carito V; Bellacosa C; Pastore G; Chirianni A; Regina G
    Atherosclerosis; 2007 Jun; 192(2):407-12. PubMed ID: 16787645
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Switching to abacavir to reduce fat wasting.
    TreatmentUpdate; 2002 Mar; 14(3):4-5. PubMed ID: 12033189
    [No Abstract]   [Full Text] [Related]  

  • 57. The Effectiveness of a Bioactive Food Compound in the Lipid Control of Individuals with HIV/AIDS.
    Dos Santos Ferreira R; de Cássia Avellaneda Guimarães R; Jardim Cury Pontes ER; Aragão do Nascimento V; Aiko Hiane P
    Nutrients; 2016 Oct; 8(10):. PubMed ID: 27740592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New drugs for HAART. Interview by Vicki Glaser.
    Feinberg J
    AIDS Patient Care STDS; 2004 Nov; 18(11):623-8. PubMed ID: 15633259
    [No Abstract]   [Full Text] [Related]  

  • 59. Metabolic changes in the patients on second-line highly active antiretroviral therapy (HAART): A prospective cohort study from north India.
    Meena DS; Rai M; Singh SK; Tapadar J; Kumar D
    J Family Med Prim Care; 2020 Mar; 9(3):1550-1554. PubMed ID: 32509648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV protease inhibitors in gut barrier dysfunction and liver injury.
    Wu X; Li Y; Peng K; Zhou H
    Curr Opin Pharmacol; 2014 Dec; 19():61-6. PubMed ID: 25105480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.